NCT07377006 Decision Support Tool to Enhance Germline Genetic Testing for Patients With Prostate Cancer
| NCT ID | NCT07377006 |
| Status | Recruiting |
| Phase | — |
| Sponsor | M.D. Anderson Cancer Center |
| Condition | Prostate Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 108 participants |
| Start Date | 2026-02-02 |
| Primary Completion | 2030-05-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 108 participants in total. It began in 2026-02-02 with a primary completion date of 2030-05-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This clinical trial identifies factors associated with completing genetic testing, aids in the development of a decision support tool, and tests how well the decision support tool works to enhance germline genetic testing in patients with prostate cancer. Germline genetic testing is a guideline-recommended standard of care for many patients with prostate cancer. Completing genetic testing can enable the use of targeted therapies, offers access to novel clinical trials, provides valuable information, and can help identify at risk family members. The decision support tool may educate patients and assist in the decision to engage with germline genetic testing.
Eligibility Criteria
Inclusion Criteria: * Diagnosed prostate cancer patients receiving care at Lyndon B. Johnson (LBJ) Hospital * Were recommended for germline genetic testing by their oncology provider * Can provide informed consent * Can communicate in English or Spanish Exclusion Criteria: * Prostate cancer patients receiving care at LBJ who are unable to participate due to a serious psychological or cognitive condition
Contact & Investigator
Debanjan Pain
PRINCIPAL INVESTIGATOR
M.D. Anderson Cancer Center
Frequently Asked Questions
Who can join the NCT07377006 clinical trial?
This trial is open to male participants only, aged 18 Years or older, studying Prostate Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07377006 currently recruiting?
Yes, NCT07377006 is actively recruiting participants. Visit ClinicalTrials.gov or contact M.D. Anderson Cancer Center to inquire about joining.
Where is the NCT07377006 trial being conducted?
This trial is being conducted at Houston, United States.
Who is sponsoring the NCT07377006 clinical trial?
NCT07377006 is sponsored by M.D. Anderson Cancer Center. The principal investigator is Debanjan Pain at M.D. Anderson Cancer Center. The trial plans to enroll 108 participants.